<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126096">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01936974</url>
  </required_header>
  <id_info>
    <org_study_id>13-27</org_study_id>
    <nct_id>NCT01936974</nct_id>
  </id_info>
  <brief_title>(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma</brief_title>
  <acronym>PGA</acronym>
  <official_title>Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Regional Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate progression-free survival with two chemotherapy regimens on
      platinum-resistant/refractory ovarian and peritoneal carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate progression-free survival (PFS)for the regimen of gemcitabine and
      bevacizumab with or without a platinum agent on platinum-resistant/refractory ovarian and
      peritoneal carcinoma
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>One Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate progression-free survival between the two regimens.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <condition>Fallopian Tube Carcinoma</condition>
  <condition>Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platinum:
Carboplatin* on day 1
*If a patient is allergic to carboplatin, then give
Cisplatin** on day 1
**If a patient is allergic to cisplatin and carboplatin, then give
Oxaliplatin on day 1
Gemcitabine on day 1 only
Bevacizumab on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine and Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine on days 1 and 8
Bevacizumab on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <arm_group_label>Gemcitabine and Bevacizumab</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <arm_group_label>Gemcitabine and Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Platinum, Gemcitabine and Bevacizumab</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥ 18 years of age with histologically confirmed, recurrent epithelial
             ovarian, fallopian tube or primary peritoneal cancer

          2. Disease progression during or within 6 months of previous platinum-based chemotherapy
             including the following 4 categories:

               1. Primary platinum-refractory: Previously untreated patients who do not achieve at
                  least a partial response to platinum-based chemotherapy

               2. Primary platinum-resistant: Previously untreated patients who have achieved at
                  least a partial response to platinum-based chemotherapy but experience a relapse
                  within a period of 6 months of its conclusion

               3. Secondary platinum-refractory: Previously treated patients have a relapse 6
                  months after the conclusion of chemotherapy, but fail to achieve at least a
                  partial response

               4. Secondary platinum-resistant: Previously treated patients have a relapse 6
                  months after the conclusion of chemotherapy, achieve at least a partial response
                  with platinum-based therapy as 2nd-line therapy, but experience relapse within 6
                  months

          3. Eastern Cooperative Oncology Group (ECOG) performance status score &lt; 2 and a life
             expectancy &gt;3 months.

          4. Absolute neutrophil count &gt; 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 8.5
             g/dL

          5. Serum creatinine ≤1.5 times the upper limit of the normal range, total bilirubin ≤ 2
             mg/dL, AST/ALT ≤ 5 times the upper limit of normal range

          6. No remaining grade 2 or higher toxicity from prior cancer therapies unless judged to
             be clinically insignificant by the Principal Investigator

          7. At least three (3) weeks from prior chemotherapy

        Exclusion Criteria:

          1. Inadequate renal function with a calculated creatinine clearance less than 51 mL/min

          2. Uncontrolled cardiac disease, congestive heart failure, angina or hypertension

          3. Myocardial infarction or unstable angina within 2 months of treatment

          4. Known human immunodeficiency virus (HIV) infection or chronic active Hepatitis B or C
             (patients are NOT required to be tested for the presence of such viruses prior to
             therapy on this protocol)

          5. Thrombotic or embolic events such as a cerebrovascular accident including transient
             ischemic attacks within the past 6 months

          6. Bleeding diathesis or significant coagulopathy

          7. Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of
             study drug

          8. Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          9. History of fistula, GI perforation or intrabdominal abscess

         10. Serious non-healing wound, ulcer, or bone fracture

         11. clinical signs or symptoms of GI obstruction and/or requirement for parenteral
             hydration or nutrition

         12. Known CNS disease except for treated brain metastasis

         13. Known platinum drug allergy

         14. Major surgery, open biopsy or significant traumatic injury within 4 weeks of first
             study drug

         15. Inability to complete informed consent process and adhere to the protocol treatment
             plan and follow-up requirements

         16. Concurrent severe illness such as active infection, or psychiatric illness/social
             situations that would limit safety and compliance with study requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiaxin Niu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Regional Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marci Pierog, RN-BC, OCN</last_name>
    <phone>623-207-3818</phone>
    <email>marci.pierog@ctca-hope.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brenda Noggy, RN BSN</last_name>
    <phone>623-207-3541</phone>
    <email>brenda.noggy@ctca-hope.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Western Regional Medical Center</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jiaxin Niu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 3, 2013</lastchanged_date>
  <firstreceived_date>September 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Jiaxin Niu</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
